Interim analysis
If the arm of combination with oxaliplatin (2-drug chemotherapy) during consolidation shows ≥ 25% response rate difference compared to single-drug arm after 72 patients, study will be interrupted (efficacy). If the arm of 2-drug consolidation chemotherapy shows less than 5% response rate difference compared to single-drug arm after 72 patients, the study will be interrupted.